Glaukos: The Second J-Code Rewrites The Risk Math

🇺🇸 Seeking Alpha (US) —

AI Summary

The article evaluates Glaukos and argues that a second J-code could materially change the company’s reimbursement and risk outlook. The analysis focuses on how coding developments may affect the medical-device company’s commercial prospects and valuation.

Markets Health Glaukos medical devices J-code reimbursement healthcare stocks risk analysis

Read original source →